All In Biotech

Drug Trial Radar · NCT04191577

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Dec 2, 2019

Primary completion

Nov 6, 2021

Study completion Dec 13, 2021

Sponsor

Lead sponsor
Cerevance Beta, Inc.Industry
Sponsor type
Industry
First posted
Dec 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.

Conditions

  • Parkinson Disease

Interventions

  • CVN424 Low DoseDrug

    CVN424

  • CVN424 High DoseDrug

    CVN424

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Study DrugTime frame: Up to Day 35

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, LLC

    Long Beach, California

  • SC3 Research - Pasadena

    Pasadena, California

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Nova Clinical Research

    Bradenton, Florida

  • Premier Clinical Research Institute

    Miami, Florida

  • Parkinson's Disease Treatment Center of SW Florida

    Port Charlotte, Florida

  • Accel Research Site - Brain and Spine Institute of Port Orange

    Port Orange, Florida

  • USF Parkinson's Disease and Movement Disorders Center

    Tampa, Florida

  • Charter Research

    Winter Park, Florida

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

  • Parkinson's Disease and Movement Disorder Center

    Kansas City, Kansas

  • Boston Clinical Trials

    Roslindale, Massachusetts

  • Quest Research Institute

    Farmington Hills, Michigan

  • Bio Behavioral Health

    Toms River, New Jersey

  • New York Neurology Associates

    New York, New York

  • M3 Wake Research

    Raleigh, North Carolina

  • Optimed Research Ltd

    Columbus, Ohio

  • Neurology Diagnostics Inc

    Dayton, Ohio

  • Prisma Health

    Greenville, South Carolina

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • Inland Northwest Research, LLC

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.